FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217143594> ?p ?o ?g. }

• W3217143594 abstract "Background: Lipid-lowering therapy is very important in secondary prevention of coronary heart disease (CHD). In many clinical trials, it has been found that Sodium Tanshinone IIA Sulfonate Injection (STS) have a lipid-lowering effect while reducing major cardiovascular events in patients with CHD. However, up to now, there is no system review on the effectiveness and safety of STS affecting blood lipids. Purpose: The aim of this review is to systematically assess the effects of STS on blood lipid levels in patients with CHD. Methods: Until Mar 2021, five databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database) were searched for randomized controlled trials (RCTs) about STS treating patients with CHD. Risk bias was assessed for included studies according to Cochrane handbook. The primary outcome was total cholesterol (TC). The secondary outcomes were triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and adverse events (AEs). Results: A total of 27 trials including 2,445 CHD patients met the eligibility criteria. Most trials had high risks in random sequence generation, allocation concealment, blinding of patients and personal, blinding of outcome assessment. Meta-analysis showed that STS significantly reduced plasma TC levels [MD = −1.34 mmol/l 95% CI (−1.59, −1.09), p &lt; 0.00001, I 2 = 98%], TG levels [MD = −0.49 mmol/l 95% CI (−0.62, −0.35), p &lt; 0.00001, I 2 = 97%], LDL-c levels [MD = −0.68 mmol/l (−0.80, −0.57), p &lt; 0.00001, I 2 = 96%], increased HDL-c levels [MD = 0.26 mmol/l (0.15, 0.37), p &lt; 0.00001, I 2 = 97%], without increasing the incidence of AEs [RR = 1.27 95% CI (0.72, 2.27), p = 0.94, I 2 = 0%] in patients with CHD. Conclusion: STS can safely and effectively reduce plasma TC, TG and LDL-c levels in patients with CHD, and improve plasma HDL-c levels. However, these findings require careful recommendation due to the low overall quality of RCTs at present. More multi-center, randomized, double-blind, placebo-controlled trials which are designed follow the CONSORT 2010 guideline are needed." @default.
• W3217143594 created "2021-12-06" @default.
• W3217143594 creator A5002597020 @default.
• W3217143594 creator A5008921782 @default.
• W3217143594 creator A5028295358 @default.
• W3217143594 creator A5029469519 @default.
• W3217143594 creator A5044063199 @default.
• W3217143594 creator A5052821031 @default.
• W3217143594 creator A5086921198 @default.
• W3217143594 creator A5089382995 @default.
• W3217143594 creator A5090758948 @default.
• W3217143594 creator A5091550310 @default.
• W3217143594 date "2021-11-24" @default.
• W3217143594 modified "2023-10-15" @default.
• W3217143594 title "Effect of Sodium Tanshinone IIA Sulfonate Injection on Blood Lipid in Patients With Coronary Heart Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials" @default.
• W3217143594 cites W1665583843 @default.
• W3217143594 cites W1969209081 @default.
• W3217143594 cites W1971308414 @default.
• W3217143594 cites W1988724742 @default.
• W3217143594 cites W1999094249 @default.
• W3217143594 cites W2023403026 @default.
• W3217143594 cites W2043042777 @default.
• W3217143594 cites W2049756201 @default.
• W3217143594 cites W2060167104 @default.
• W3217143594 cites W2096237235 @default.
• W3217143594 cites W2097192370 @default.
• W3217143594 cites W2105397247 @default.
• W3217143594 cites W2112000706 @default.
• W3217143594 cites W2134833483 @default.
• W3217143594 cites W2155053630 @default.
• W3217143594 cites W2156098321 @default.
• W3217143594 cites W2157823046 @default.
• W3217143594 cites W2163810943 @default.
• W3217143594 cites W2171313296 @default.
• W3217143594 cites W2340699148 @default.
• W3217143594 cites W2519634482 @default.
• W3217143594 cites W2520525934 @default.
• W3217143594 cites W2774673446 @default.
• W3217143594 cites W2801235202 @default.
• W3217143594 cites W2893607518 @default.
• W3217143594 cites W2898998405 @default.
• W3217143594 cites W2991792334 @default.
• W3217143594 cites W3011371150 @default.
• W3217143594 cites W3087660966 @default.
• W3217143594 cites W3108605169 @default.
• W3217143594 cites W3139489342 @default.
• W3217143594 doi "https://doi.org/10.3389/fcvm.2021.770746" @default.
• W3217143594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34901229" @default.
• W3217143594 hasPublicationYear "2021" @default.
• W3217143594 type Work @default.
• W3217143594 sameAs 3217143594 @default.
• W3217143594 citedByCount "8" @default.
• W3217143594 countsByYear W32171435942022 @default.
• W3217143594 countsByYear W32171435942023 @default.
• W3217143594 crossrefType "journal-article" @default.
• W3217143594 hasAuthorship W3217143594A5002597020 @default.
• W3217143594 hasAuthorship W3217143594A5008921782 @default.
• W3217143594 hasAuthorship W3217143594A5028295358 @default.
• W3217143594 hasAuthorship W3217143594A5029469519 @default.
• W3217143594 hasAuthorship W3217143594A5044063199 @default.
• W3217143594 hasAuthorship W3217143594A5052821031 @default.
• W3217143594 hasAuthorship W3217143594A5086921198 @default.
• W3217143594 hasAuthorship W3217143594A5089382995 @default.
• W3217143594 hasAuthorship W3217143594A5090758948 @default.
• W3217143594 hasAuthorship W3217143594A5091550310 @default.
• W3217143594 hasBestOaLocation W32171435941 @default.
• W3217143594 hasConcept C126322002 @default.
• W3217143594 hasConcept C139572402 @default.
• W3217143594 hasConcept C142724271 @default.
• W3217143594 hasConcept C168563851 @default.
• W3217143594 hasConcept C197934379 @default.
• W3217143594 hasConcept C204787440 @default.
• W3217143594 hasConcept C27081682 @default.
• W3217143594 hasConcept C2771230 @default.
• W3217143594 hasConcept C2776478404 @default.
• W3217143594 hasConcept C2778163477 @default.
• W3217143594 hasConcept C2778270857 @default.
• W3217143594 hasConcept C535046627 @default.
• W3217143594 hasConcept C71924100 @default.
• W3217143594 hasConcept C95190672 @default.
• W3217143594 hasConceptScore W3217143594C126322002 @default.
• W3217143594 hasConceptScore W3217143594C139572402 @default.
• W3217143594 hasConceptScore W3217143594C142724271 @default.
• W3217143594 hasConceptScore W3217143594C168563851 @default.
• W3217143594 hasConceptScore W3217143594C197934379 @default.
• W3217143594 hasConceptScore W3217143594C204787440 @default.
• W3217143594 hasConceptScore W3217143594C27081682 @default.
• W3217143594 hasConceptScore W3217143594C2771230 @default.
• W3217143594 hasConceptScore W3217143594C2776478404 @default.
• W3217143594 hasConceptScore W3217143594C2778163477 @default.
• W3217143594 hasConceptScore W3217143594C2778270857 @default.
• W3217143594 hasConceptScore W3217143594C535046627 @default.
• W3217143594 hasConceptScore W3217143594C71924100 @default.
• W3217143594 hasConceptScore W3217143594C95190672 @default.
• W3217143594 hasFunder F4320321001 @default.
• W3217143594 hasFunder F4320322935 @default.
• W3217143594 hasFunder F4320323484 @default.
• W3217143594 hasLocation W32171435941 @default.
• W3217143594 hasLocation W32171435942 @default.
• W3217143594 hasLocation W32171435943 @default.

• next